Sionna Therapeutics Shares Plummet 92% After Cystic Fibrosis Drug Trial Failure
Product·2 articles across 2 outlets·↩ Updated
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Sionna Therapeutics' stock plummeted 92% following the failure of its cystic fibrosis drug in a mid-stage trial. The drug did not provide a meaningful additive impact when combined with Vertex's top-selling Trikafta, leading to a significant collapse in company shares.
In response to the trial results, Sionna has decided to discontinue its cystic fibrosis add-on program and is taking actions to preserve capital while evaluating next steps. This outcome removes a potential challenger to Vertex Pharmaceuticals, which benefits from the failure of Sionna's drug.
Sionna TherapeuticsVertex Pharmaceuticals
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates”
SEC Filing — Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results - Johnson Fistel Investigates“Sionna Therapeutics stock plunged 92% after its cystic fibrosis drug flopped in a mid-stage trial”
quartz — Sionna Therapeutics stock plunged 92% after its cystic fibrosis drug flopped in a mid-stage trial“<p>Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.</p>”
biopharma dive — Sionna cystic fibrosis drug fails key trial, removing threat to Vertex“A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.”
stat news — STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial“Sionna Therapeutics has axed a cystic fibrosis add-on program after flunking a phase 2 trial, eliminating a would-be challenger to Vertex Pharmaceuticals’ empire.”
fierce biotech — <a href="/biotech/sionnas-cystic-fibrosis-flop-significant-positive-vertex" hreflang="en">Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex</a>
Earlier versions
- Aug 10, 2:15 PM — Vertex Pharma Stock Surges After Sionna Therapeutics Plummets 90% (2/2)
- Aug 10, 8:30 PM — Vertex Pharma Stock Surges After Sionna Therapeutics Cystic Fibrosis Drug Fails Trial (3/3)